Injective (INJ) Price Decline Amid Market Volatility
Injective (INJ) is trading at $4.54 USD with a 24-hour decline of 5.54%, as the token faces broader market headwinds despite recent infrastructure upgrades and institutional developments.
Recent Technical Developments
The Vulcan upgrade went live on June 9, refactoring core infrastructure to deliver lower fees, native USDC settlement, support for new real-world asset (RWA) markets, and an advanced oracle engine. This directly enhances the chain's utility for high-volume derivatives and RWA trading, which could drive higher protocol fees and demand for INJ for gas and staking.
However, the immediate market reaction was a typical "sell the news" pullback.
Institutional Expansion and Regulatory Progress
The launch of Injective's M-INJ, a regulated investment product in Thailand, was announced on June 5, 2026, allowing both retail and institutional investors supervised exposure to INJ. U.S.-regulated INJ futures launched on the CFTC-approved Bitnomial exchange in April 2026, while Merkle Capital launched M-INJ, the first regulated INJ fund in Asia, supervised by Thailand's SEC.
Deflationary Tokenomics Support
The June 2026 buyback was valued at over $315,000. Governance proposal IIP-617 passed with 99.9% approval, permanently doubling the deflation rate by combining reduced token issuance with a burn mechanism.
Market Sentiment and Price Outlook
With a price decline of -19.70% in the last 7 days, Injective is underperforming the global cryptocurrency market which is down -4.70%. The consensus on INJ is bullish, driven by a belief that its relentless ecosystem development—spanning regulated access, AI integration, and institutional partnerships—is fundamentally undervalued by the current market price. While short-term traders are cautiously watching support levels, the overarching narrative is one of building for a significant breakout.